Piper Sandler Reiterates Overweight Rating on Moderna (MRNA)
August 3, 2026 10:05 AM
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $77.00 price target on Moderna (NASDAQ: MRNA).The analyst commented: "COVID ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
